Description: Belizatinib (TSR-011) is an effective, oral and dual inhibitor of ALK (IC50: 0.7 nM, wild-type recombinant ALK) and TRKA, TRKB, and TRKC. Target: Trk receptor, ALK. Smiles: CC(C)NC(=O)[C@H]1CC[C@H](CC1)n1c(NC(=O)c2ccc(F)cc2)nc2ccc(CN3CCC(CC3)C(C)(C)O)cc12. References: Sullivan I, et al. ALK inhibitors...

Belizatinib is an inhibitor of anaplastic lymphoma kinase (ALK) and tropomyosin-related kinases A/B/C (IC50s = 0.7 and 98%. Formulation: (Request formulation change), A crystalline solid. Solubility: DMF: 30 mg/ml, DMSO: 30 mg/ml, Ethanol: 30 mg/ml. lambdamax: 324 nm. SMILES:...